Kelly Jackson

Ask Kelly About...
  • Biotech Strategy & Operations
  • Research & Development
  • Clinical Development


Kelly Jackson

Jackson is presently leveraging 20 years of experience in biotechnology and pharmaceutical research, discovery and development to provide strategy and operations leadership for a seed-funded Newco in Boston.

Prior to joining the Newco team, she was executive director of strategy and operations at Fulcrum Therapeutics, where she led portfolio management for a pipeline that evolved from series A-funded preclinical projects into a public company portfolio of programs in all phases of clinical development. She was previously a director in R&D program leadership and business operations at Biogen. During her tenure, she oversaw the business process portfolio and was responsible for the prioritization and collaborative execution of initiatives driving efficiency, compliance and business agility. Jackson has also served as a member of the global clinical trial operations team at Merck, leading both international clinical development projects and transformation initiatives after joining the organization as a clinical research associate.

Prior to transitioning to an industry role, she served as the director of research operations at the mood disorders research program at Case Western Reserve University/University Hospitals of Cleveland. In this role, she led a clinical research infrastructure including investigator-initiated, sponsor-driven and NIH clinical research protocols.

Jackson earned her bachelor’s degree in psychology and criminal justice from Mercyhurst University and a master’s degree in clinical counseling from John Carroll University.